赛马鲁肽
医学
恩帕吉菲
艾塞那肽
血压
荟萃分析
2型糖尿病
利拉鲁肽
杜拉鲁肽
内科学
卡格列净
二甲双胍
糖尿病
随机对照试验
达帕格列嗪
药理学
内分泌学
作者
Απόστολος Τσάπας,Thomas Karagiannis,Panagiota Kakotrichi,Ioannis Avgerinos,Chrysanthi Mantsiou,Georgios Tousinas,Apostolos Manolopoulos,Aris Liakos,Konstantinos Malandris,David R. Matthews,Eleni Bekiari
摘要
Semaglutide and SGLT-2 inhibitors conferred reductions both in body weight and blood pressure that were sustainable for over 1 year of treatment. These agents may be preferable treatment options for patients with type 2 diabetes who are overweight/obese and/or hypertensive.
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
(2025-6-4)
大力的灵雁
GingerF
花花菌
Criminology34
湖工大保卫处
斯文的白玉
贪玩的秋柔
OsamaKareem
claudio12
YifanWang
Yini
张欢馨
zzzz
活泼的远航
无极微光
MchemG
danruolan
vin
雨jia
morena
皖公网安备34019202002308
